Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
If you see __ __ __ at the site of tumor, you know that there was an immune reaction.
|
Mononuclear cell infiltrates.
|
|
How do draining lymph nodes change with an immune system response?
|
Hyperplasia.
|
|
MAGE, BAGE, and GAGE genes encode __ antigens. Which T cells detect these?
|
Melanoma. CTL.
|
|
Mucin core proteins are expressed by what three carcinomas? Why can mucin proteins not avoid immune detection?
|
Breast, ovarian, and pancreatic carcinomas. Mucin is underglycosylated, which allows antigen processing and presentation.
|
|
Name the tumor associated antigens associated with the following cancers: breast ca, ovarian ca, prostate ca, liver ca.
|
Breast - HER2/Nu. Ovarian - Ca125. Prostate - PSA. Liver ca - AFP.
|
|
What is the hallmark of malignant disease?
|
Dedifferentiation.
|
|
In terms of tumor association antigens, __ is less specific but more sensitive for ovarian cancer. __ is sensitivity and more specific for prostate cancer.
|
CA125. PSA.
|
|
How is tumor immunity related to self-reactive T cells?
|
Tumor cells can evade immune responses because the thymus eliminated most of the self-reactive T cells, which could kill the tumor.
|
|
If T regulatory cell recruitment is prevented, what does that mean for the immune system’s ability to fight tumors?
|
Lack of Treg recruitment increases the immune system’s ability to fight the tumor; Tregs = suppression.
|
|
Tumor elimination by cyclophosphamide depends on inducing of __ __.
|
CD+4 T cells.
|
|
What is required for therapeutic vaccines to sustain a CTL response?
|
T helper.
|
|
These cells taken from the patient can be used in therapeutic vaccines very well.
|
Dendritic cells.
|
|
Patients that receive DC vaccines must be __.
|
Immunocompetent.
|
|
__ __ __ is contraindicated for DC vaccines.
|
Advanced metastatic disease.
|
|
These two cytokines can induce DC maturation.
|
TNF-alpha and IL-1b.
|
|
__ is the first cellular therapy for cancer approved.
|
Provenge.
|
|
This form of immunotherapy is recommended for immunocompromised patients.
|
T cell immunotherapy.
|
|
This form of T cell immunotherapy shows up to 50% response rates in patients with solid metastatic tumors.
|
Non-myeloablative lymphodepletion enhancement.
|
|
Ontak consists of __ + __. How does it help fight tumors?
|
IL-2 + diphtheria toxin. It inhibits Treg, which facilitate T cell suppression.
|
|
These cytokines are used for passive immunotherapy. Which one can cause depression, neuropathy, and hematologic abnormalities?
|
IL-2, TNF, IFN-alpha, and IFN-gamma. IL-2.
|
|
__ has been largely unsuccessful in treating tumors.
|
Active immunization.
|
|
Chimeric immunotherapy often combines __ and __ with antibodies. What does this conjugation often cause?
|
Combines drugs and toxins to antibodies. Frequently have systemic effects and hepatoxicity.
|
|
Rituximab is recombined anti-_.
|
Anti-CD20.
|
|
Herceptin is specific against __.
|
HER2-neu.
|
|
Avastin inhibits __ and is used against colorectal cancer.
|
Inhibits VEGF.
|
|
Name four ways that tumors can evade immune detection.
|
Decreased HLA class expression, decreased costimulatory molecules for T cell activation, secretion of immunosuppressive cytokines, and expression of chemokines that drive Treg recruitment.
|
|
How do you distinguish between B and T cell lymphomas?
|
Immunohistochemistry shows that B cell lymphomas express CD19 and CD20 while T cell lymphomas express CD25.
|
|
Which cell surface antigen does Burkitt lymphoma express?
|
CD10.
|